ATP, 1%, 1 ml, 10 pcs.

Sodium adenosine triphosphate (ATP) is a metabolic agent, has an antiarrhythmic effect, also has a hypotensive effect, dilates coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. It is found in many organs and tissues, but most of all in the skeletal muscles. It improves metabolism and energy supply of tissues.

Transfer of ATP causes decrease of arterial pressure and relaxation of smooth muscles, improves nerve impulse conduction in vegetative ganglia and transfer of excitation from vagus nerve to heart, increases myocardial contractility. After parenteral administration it penetrates the cells of organs where it splits into adenosine and inorganic phosphate with release of energy.

Indications

In the complex therapy of muscular dystrophy and atrophy; for relief of paroxysms of supraventricular tachycardia; in peripheral vascular spasms (intermittent claudication, Raynaud’s disease, obliterating thrombangiitis).

In central, peripheral and mixed forms of hereditary retinal pigmentary degeneration.

Active ingredient

Composition

1 ml of solution for intravenous injection contains:

acting substance:

adenosine triphosphoric acid 10 mg.

Auxiliary substances:

Sodium hydroxide solution 2 M (to pH 7.0-7.3),

water for injection.

How to take, the dosage

Sodium adenosine triphosphate is administered intramuscularly or intravenously.

For the treatment of muscular dystrophies, peripheral circulatory disorders in the first 2-3 days 1 ml intramuscularly once a day is prescribed, on subsequent days – 1 ml 2 times a day or immediately 2 ml once a day. The course of treatment is 30-40 days. If necessary the course shall be repeated in 1-2 months.

In case of hereditary retinal pigmentary degeneration 5 ml by intramuscular injection 2 times a day, 6-8 hours apart, daily for 15 days. If necessary, the courses can be repeated at intervals of 8-12 months.

To stop supraventricular tachyarrhythmias, inject intravenously 1-2 ml for 5-10 seconds (effect observed after 20-40 seconds). If necessary, the same dose is administered again after 2-3 minutes.

Interaction

When used together with dipyridamole, the effects of dipyridamole, in particular the vasodilator effect, are enhanced.

There is some antagonism when co-administering the drug with purine derivatives (caffeine and theophylline).

The drug should not be administered concomitantly with cardiac glycosides in high doses because of an increased risk of cardiovascular adverse reactions.

Concomitant use with xanthinol nicotinate decreases the effect of sodium adenosine triphosphate.

Carbamazepine may increase the effects of adenosine and lead to the development of blockade.

Special Instructions

Intravenous administration of the drug should generally be done in a hospital setting, under medical supervision, with monitoring of heart function, slowly, and after which it is advisable to measure the blood pressure.

Contraindications

Side effects

Central nervous system: headache, dizziness, momentary loss of consciousness, feeling of compression in the head, phobias.

Visual organs: blurred vision.

Gastrointestinal tract: nausea, metallic taste in the mouth, increased gastrointestinal motility (when administered intravenously).

Cardiovascular system disorders: palpitations, sensation of discomfort in the chest, tachycardia or bradycardia, arterial hypotension, arrhythmia, AV conduction disorders (atrioventricular block), asystole.

Musculoskeletal system: pain in the arms, back, neck.

Urinary system disorders: increased diuresis.

Respiratory system: shortness of breath, bronchospasm.

Skin and subcutaneous tissue changes: facial hyperemia, itching, skin rash.

Disorders at the injection site: tingling sensation.

Allergic reactions: hypersensitivity reactions, allergic dermatitis, urticaria, anaphylactic shock.

General disorders: increased sweating, hyperthermia, feeling of fever.

Overdose

Symptoms: dizziness, arterial hypotension, transient loss of consciousness, arrhythmia, atrioventricular block of degree II and III, asystole, bronchospasm, ventricular disorders, sinus bradycardia and tachycardia. The development of allergic reactions is also possible.

Treatment.Injection of the drug is stopped immediately and cardiotonic agents are prescribed. Therapy is symptomatic. Xanthines (eufylline, theophylline) are competitive adenosine antagonists.